title: Cyclosporine in addition to infliximab and methotrexate in refractory rheumatoid arthritis.
authors.forename: A
authors.initials: A
authors.lastname: Marchesoni
authors.forename: P
authors.initials: P
authors.lastname: Sarzi Puttini
authors.forename: R
authors.initials: R
authors.lastname: Gorla
authors.forename: R
authors.initials: R
authors.lastname: Caporali
authors.forename: C
authors.initials: C
authors.lastname: Arnoldi
authors.forename: F
authors.initials: F
authors.lastname: Atzeni
authors.forename: M
authors.initials: M
authors.lastname: Vianelli
authors.forename: F Bobbio
authors.initials: FB
authors.lastname: Pallavicini
mesh_terms: D000328:Adult; D000368:Aged; D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000009:adverse effects; D018501:Antirheumatic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D016572:Cyclosporine / Q000008:administration & dosage* / Q000009:adverse effects; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D000069285:Infliximab; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage* / Q000009:adverse effects; D008875:Middle Aged
chemical_list: D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D016572:Cyclosporine; D000069285:Infliximab; D008727:Methotrexate